• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利:CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验

甲氨蝶呤耐药的CCRF-CEM细胞中膜转运受损涉及早期翻译终止和突变型还原型叶酸载体的周转增加。

Impaired membrane transport in methotrexate-resistant CCRF-CEM cells involves early translation termination and increased turnover of a mutant reduced folate carrier.

作者信息

Wong S C, Zhang L, Witt T L, Proefke S A, Bhushan A, Matherly L H

机构信息

Experimental and Clinical Therapeutics Program, Barbara Ann Karmanos Cancer Institute, Wayne State University, Detroit, Michigan 48201, USA.

出版信息

J Biol Chem. 1999 Apr 9;274(15):10388-94. doi: 10.1074/jbc.274.15.10388.

DOI:10.1074/jbc.274.15.10388
PMID:10187828
Abstract

The basis for impaired reduced folate carrier (RFC) activity in methotrexate-resistant CCRF-CEM (CEM/Mtx-1) cells was examined. Parental and CEM/Mtx-1 cells expressed identical levels of the 3. 1-kilobase RFC transcript. A approximately 85-kDa RFC protein was detected in parental cells by photoaffinity labeling and on Western blots with RFC-specific antiserum. In CEM/Mtx-1 cells, RFC protein was undetectable. By reverse transcriptase-polymerase chain reaction and sequence analysis, G to A point mutations were identified in CEM/Mtx-1 transcripts at positions 130 (P1; changes glycine 44 --> arginine) and 380 (P2; changes serine 127 --> asparagine). A 4-base pair (CATG) insertion detected at position 191 (in 19-30% of cDNA clones) resulted in a frameshift and early translation termination. Wild-type RFC was also detected (0-9% of clones). Wild-type RFC and double-mutated RFC (RFCP1+P2) cDNAs were transfected into transport-impaired K562 and Chinese hamster ovary cells. Although RFC transcripts paralleled wild-type protein, for the RFCP1+P2 transfectants, disproportionately low RFCP1+P2 protein was detected. This reflected an increased turnover of RFCP1+P2 over wild-type RFC. RFCP1+P2 did not restore methotrexate transport; however, uptake was partially restored by constructs with single mutations at the P1 or P2 loci. Cumulatively, our results show that loss of transport function in CEM/Mtx-1 cells results from complete loss of RFC protein due to early translation termination and increased turnover of a mutant RFC protein.

摘要

研究了甲氨蝶呤耐药的CCRF - CEM(CEM/Mtx - 1)细胞中叶酸载体(RFC)活性降低的原因。亲本细胞和CEM/Mtx - 1细胞表达相同水平的3.1千碱基RFC转录本。通过光亲和标记和用RFC特异性抗血清进行的蛋白质印迹法在亲本细胞中检测到一种约85 kDa的RFC蛋白。在CEM/Mtx - 1细胞中未检测到RFC蛋白。通过逆转录酶 - 聚合酶链反应和序列分析,在CEM/Mtx - 1转录本的130位(P1;甘氨酸44变为精氨酸)和380位(P2;丝氨酸127变为天冬酰胺)鉴定到G到A的点突变。在191位检测到一个4碱基对(CATG)插入(在19% - 30%的cDNA克隆中),导致移码和早期翻译终止。也检测到野生型RFC(0% - 9%的克隆)。将野生型RFC和双突变RFC(RFCP1 + P2)cDNA转染到转运功能受损的K562和中国仓鼠卵巢细胞中。尽管RFC转录本与野生型蛋白平行,但对于RFCP1 + P2转染子,检测到的RFCP1 + P2蛋白比例过低。这反映了RFCP1 + P2相对于野生型RFC的周转率增加。RFCP1 + P2不能恢复甲氨蝶呤转运;然而,在P1或P2位点有单突变的构建体部分恢复了摄取。总体而言,我们的结果表明,CEM/Mtx - 1细胞中转运功能的丧失是由于早期翻译终止导致RFC蛋白完全丧失以及突变RFC蛋白的周转率增加所致。

相似文献

1
Impaired membrane transport in methotrexate-resistant CCRF-CEM cells involves early translation termination and increased turnover of a mutant reduced folate carrier.甲氨蝶呤耐药的CCRF-CEM细胞中膜转运受损涉及早期翻译终止和突变型还原型叶酸载体的周转增加。
J Biol Chem. 1999 Apr 9;274(15):10388-94. doi: 10.1074/jbc.274.15.10388.
2
Regulation of carrier-mediated transport of folates and antifolates in methotrexate-sensitive and-resistant leukemia cells.甲氨蝶呤敏感和耐药白血病细胞中载体介导的叶酸和抗叶酸转运的调节
Adv Enzyme Regul. 1997;37:59-76. doi: 10.1016/s0065-2571(96)00012-x.
3
A structurally altered human reduced folate carrier with increased folic acid transport mediates a novel mechanism of antifolate resistance.一种结构改变且叶酸转运增加的人类还原型叶酸载体介导了一种新的抗叶酸耐药机制。
J Biol Chem. 1998 Nov 13;273(46):30189-98. doi: 10.1074/jbc.273.46.30189.
4
P-glycoprotein-mediated methotrexate resistance in CCRF-CEM sublines deficient in methotrexate accumulation due to a point mutation in the reduced folate carrier gene.在CCRF-CEM亚系中,由于还原型叶酸载体基因的点突变导致甲氨蝶呤积累缺陷,P-糖蛋白介导了对甲氨蝶呤的耐药性。
Int J Cancer. 1998 Oct 5;78(2):176-81. doi: 10.1002/(sici)1097-0215(19981005)78:2<176::aid-ijc10>3.0.co;2-9.
5
Isolation of human cDNAs that restore methotrexate sensitivity and reduced folate carrier activity in methotrexate transport-defective Chinese hamster ovary cells.在甲氨蝶呤转运缺陷的中国仓鼠卵巢细胞中恢复甲氨蝶呤敏感性并降低叶酸载体活性的人cDNA的分离。
J Biol Chem. 1995 Jul 21;270(29):17468-75. doi: 10.1074/jbc.270.29.17468.
6
Association of deletions and translocation of the reduced folate carrier gene with profound loss of gene expression in methotrexate-resistant K562 human erythroleukemia cells.还原型叶酸载体基因的缺失和易位与甲氨蝶呤耐药的K562人红白血病细胞中基因表达的显著丧失之间的关联。
Biochem Pharmacol. 2001 Mar 15;61(6):665-75. doi: 10.1016/s0006-2952(01)00535-4.
7
Clustering of mutations in the first transmembrane domain of the human reduced folate carrier in GW1843U89-resistant leukemia cells with impaired antifolate transport and augmented folate uptake.在抗叶酸转运受损且叶酸摄取增加的GW1843U89耐药白血病细胞中,人还原型叶酸载体第一跨膜结构域的突变聚集。
J Biol Chem. 2000 Oct 6;275(40):30855-63. doi: 10.1074/jbc.M003988200.
8
Effects of the loss of capacity for N-glycosylation on the transport activity and cellular localization of the human reduced folate carrier.
Biochim Biophys Acta. 1998 Oct 15;1375(1-2):6-12. doi: 10.1016/s0005-2736(98)00118-7.
9
A single amino acid difference within the folate transporter encoded by the murine RFC-1 gene selectively alters its interaction with folate analogues. Implications for intrinsic antifolate resistance and directional orientation of the transporter within the plasma membrane of tumor cells.由小鼠RFC-1基因编码的叶酸转运蛋白内的单个氨基酸差异选择性地改变其与叶酸类似物的相互作用。对肿瘤细胞质膜内固有抗叶酸耐药性和转运蛋白的定向排列的影响。
J Biol Chem. 1998 Jan 30;273(5):2526-31. doi: 10.1074/jbc.273.5.2526.
10
Multiple mechanisms of resistance to methotrexate and novel antifolates in human CCRF-CEM leukemia cells and their implications for folate homeostasis.人CCRF-CEM白血病细胞对甲氨蝶呤和新型抗叶酸药物的多种耐药机制及其对叶酸稳态的影响
Biochem Pharmacol. 2002 Jan 15;63(2):105-15. doi: 10.1016/s0006-2952(01)00824-3.

引用本文的文献

1
Pharmacogenomics on the Treatment Response in Patients with Psoriasis: An Updated Review.药物基因组学在银屑病患者治疗反应中的作用:更新综述。
Int J Mol Sci. 2023 Apr 15;24(8):7329. doi: 10.3390/ijms24087329.
2
Molecular mechanism of substrate recognition by folate transporter SLC19A1.叶酸转运蛋白SLC19A1识别底物的分子机制。
Cell Discov. 2022 Dec 28;8(1):141. doi: 10.1038/s41421-022-00508-w.
3
Impact of genetic variants of RFC1, DHFR and MTHFR in osteosarcoma patients treated with high-dose methotrexate.RFC1、DHFR和MTHFR基因变异对接受大剂量甲氨蝶呤治疗的骨肉瘤患者的影响。
Pharmacogenomics J. 2015 Oct;15(5):385-90. doi: 10.1038/tpj.2015.11. Epub 2015 Mar 17.
4
Biology of the major facilitative folate transporters SLC19A1 and SLC46A1.主要易化型叶酸转运蛋白SLC19A1和SLC46A1的生物学特性
Curr Top Membr. 2014;73:175-204. doi: 10.1016/B978-0-12-800223-0.00004-9.
5
The major facilitative folate transporters solute carrier 19A1 and solute carrier 46A1: biology and role in antifolate chemotherapy of cancer.主要促进叶酸转运蛋白溶质载体 19A1 和溶质载体 46A1:生物学及在癌症抗叶酸化疗中的作用。
Drug Metab Dispos. 2014 Apr;42(4):632-49. doi: 10.1124/dmd.113.055723. Epub 2014 Jan 6.
6
Interleukin-6 regulates anti-arthritic effect of methotrexate via reduction of SLC19A1 expression in a mouse arthritis model.白细胞介素-6 通过降低 SLC19A1 表达调控甲氨蝶呤治疗关节炎的作用。
Arthritis Res Ther. 2012 Apr 30;14(2):R96. doi: 10.1186/ar3821.
7
SLC19A1 pharmacogenomics summary.SLC19A1药物基因组学概述。
Pharmacogenet Genomics. 2010 Nov;20(11):708-15. doi: 10.1097/FPC.0b013e32833eca92.
8
Correlation between polymorphisms of the reduced folate carrier gene (SLC19A1) and survival after pemetrexed-based therapy in non-small cell lung cancer: a North Central Cancer Treatment Group-based exploratory study.基于北中央癌症治疗组的探索性研究:还原型叶酸载体基因(SLC19A1)多态性与培美曲塞为基础的治疗后非小细胞肺癌患者生存的相关性。
J Thorac Oncol. 2010 Sep;5(9):1346-53. doi: 10.1097/JTO.0b013e3181ec18c4.
9
Identification of the minimal functional unit of the homo-oligomeric human reduced folate carrier.鉴定同型寡聚体人还原叶酸载体的最小功能单位。
J Biol Chem. 2010 Feb 12;285(7):4732-40. doi: 10.1074/jbc.M109.086033. Epub 2009 Dec 17.
10
Phase II trial of pemetrexed plus bevacizumab for second-line therapy of patients with advanced non-small-cell lung cancer: NCCTG and SWOG study N0426.培美曲塞联合贝伐珠单抗二线治疗晚期非小细胞肺癌的 II 期临床试验:NCCTG 和 SWOG 研究 N0426。
J Clin Oncol. 2010 Feb 1;28(4):614-9. doi: 10.1200/JCO.2009.23.6406. Epub 2009 Oct 19.